1. Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas 
Xin Huang, MD, Joseph Greene, BA, James Pao, BA, Erin Mulvey, BA, Sophia X. Zhou, Deepali Sachdev, PhD, Douglas Yee, MD, Christoph Rader, PhD, Catherine M. Albert, MD, Haein Park, PhD, Yaya Chu, PhD, Carl Hamby, PhD, David Loeb, MD, PhD, Mitchell S. Cairo, MD, Xianzheng Zhou, PhD 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 2, Pages S184-S185 (February 2014)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
In vitro and in vivo anti-sarcoma activity of IGF-1R and ROR1 CAR T cells. (A) Cytotoxicity assays. (B) Anti-sarcoma activity in a systemic model. SaOS2-fflucN cells (7.5×105) were i.v. injected into NSG mice for 5 days, treated with mock, IGF-1R CAR and ROR1 CAR T cells (1×107) on day 6 and 9, and imaged for tumor control on day 11, 17, 24, 31 and 38. (C) Survival benefit of CAR T cells in a local sarcoma model. SaOS2-fflucN (3×105) cells were i.p. injected in NOD/SCID mice, untreated or treated with mock, IGF-1R (IGZ) CAR and ROR1 CAR T cells on day 3, 5 and 7, and monitored for survival.
Biology of Blood and Marrow Transplantation  , S184-S185DOI: ( /j.bbmt )
Copyright © Terms and Conditions